MedTrace Logo

Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

NCT02844816 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2025-05-22

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well atezolizumab works in treating patients with non-muscle invasive bladder cancer that has come back (recurrent) and has not responded to treatment (refractory) with Bacillus Calmette-Guerin (BCG). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Conditions

  • Recurrent Bladder Urothelial Carcinoma
  • Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7
  • Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7
  • Stage I Bladder Urothelial Carcinoma AJCC v6 and v7

Interventions

DRUG

Atezolizumab

Given IV

Sponsors & Collaborators

  • Canadian Cancer Trials Group

    collaborator NETWORK

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Peter C Black · SWOG Cancer Research Network

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-13
Primary Completion
2023-06-01
Completion
2024-06-26
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02844816 on ClinicalTrials.gov